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HYPERTROPHIC CARDIOMYOPATHY 
 
 
Classification 
A cardiomyopathy is defined as a disorder in which the heart muscle is 
structurally and functionally abnormal, in the absence of coronary artery 
disease, hypertension, valvular disease and congenital heart disease sufficient to 
cause the observed myocardial abnormality.  
 
 
                                      
 
Figure 1. Summary of proposed classification system. ARVC, arrhythmogenic right ventricular 
cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; RCM, 
restrictive cardiomyopathy  
 
In this context, familial refers to the occurrence, in more than a family member, 
of either the same disorder or a phenotype that is caused by the same genetic 
mutation and not to acquired cardiac or systemic disease in which the clinical 
phenotype is influenced by genetic polymorphism. Most familial 
cardiomyopathies are monogenic disorders. A monogenic cardiomyopathy can 
be sporadic when the causative mutation is de novo.  
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Non-familial cardiomyopathies are clinically defined by the presence of a 
cardiomyopathy in the index patient and the absence of disease in other family 
members (based on pedigree analysis and clinical evaluation). They are 
subdivided into idiopathic (no identifiable cause) and acquired 
cardiomyopathies in which ventricular dysfunction is a complication of the 
disorder rather than an intrinsic feature of the disease.1 
 
 
Table 1. Examples of different diseases that cause cardiomyopathies. 
 
 
Definition  
Hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left 
ventricular (LV) wall thickness that is not solely explained by abnormal loading 
condition.1 
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Epidemiology 
A number of methodologically diverse studies in North America, Europe, Asia 
and Africa report a prevalence of unexplained increase in LV wall thickness in 
the range of 0.02–0.23% in adults.  Many show an age-related prevalence, with 
much lower rates in patients diagnosed under the age of 25 years. While HCM is 
most frequently transmitted as an autosomal-dominant trait most studies report 
a small male preponderance. This finding remains unexplained but might reflect 
bias in screening strategies as well as genetic and hormonal modifiers. The 
prevalence of HCM in different racial groups is similar. 
2
 
 
Diagnosis 
The diagnosis of HCM rests on the detection of increased LV wall thickness by 
any imaging modality, but the disease phenotype also includes myocardial 
fibrosis, morphologic abnormalities of the mitral valve apparatus, abnormal 
coronary microcirculatory function and electrocardiographic abnormalities.2 
 
Diagnostic criteria in adults: 
In an adult, HCM is defined by a wall thickness ≥15 mm in one or more LV 
myocardial segments as measured by any imaging technique (echocardiography, 
cardiac magnetic resonance imaging (CMR) or computed tomography (CT)) that 
is not explained solely by loading conditions. Genetic and non-genetic disorders 
can present with lesser degrees of wall thickening (13–14 mm); in these cases, 
the diagnosis of HCM requires evaluation of other features including family 
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history, non-cardiac symptoms and signs, electrocardiogram (ECG) 
abnormalities, laboratory tests and multi-modality cardiac imaging.2 The clinical 
diagnosis of HCM in first-degree relatives of patients with unequivocal disease 
(LVH ≥15 mm) is based on the presence of otherwise unexplained increased LV 
wall thickness ≥13 mm in one or more LV myocardial segments, as measured 
using any cardiac imaging technique (echocardiography, CMR or CT).3 
 
Left ventricle outflow obstruction and systolic anterior movement of mitral valve 
leaflet 
Left ventricular outflow tract obstruction (LVOTO) does play a major role in the 
pathophysiology of a subgroup of patients with HCM. It may be present at rest, 
provocable (mild at rest but significant with provocation), or latent (not present 
at rest but evident with provocation). Although altered diastolic filling is evident 
in all patients with hypertrophic cardiomyopathy, it is the high contraction load 
imposed by the obstruction that significantly worsens ventricular filling and 
relaxation. Other mechanisms by which obstruction produces symptoms are 
limitation of cardiac output, increased myocardial oxygen demand, and 
decreased coronary perfusion pressure. In addition, obstruction is associated 
with distortion of the mitral valve apparatus, resulting in secondary mitral 
regurgitation, further elevating left atrial pressure, and contributing 
substantially to severe symptoms of dyspnea.4 The mechanism by which 
obstruction is produced is complex. It was initially thought that the obstruction 
was the result of the hypertrophied septum projecting into the LVOT, causing a 
Venturi effect that would “suck” the mitral valve leaflets into the left ventricular 
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outflow tract.
5 Through intricate flow studies in the left ventricular cavity, it has 
been shown that obstruction can be secondary to an anterior displacement of the 
mitral valve apparatus coupled with accelerated flow around the septal 
hypertrophy, which produces a drag force to “push” the mitral leaflets into the 
outflow tract.6 Other morphological features that contribute to LVOTO include 
papillary muscle abnormalities (hypertrophy, anterior and internal 
displacement, direct insertion into the anterior mitral valve leaflet) and mitral 
leaflet abnormalities such as elongation or accessory tissue.
7 
Irrespective of the 
mechanism, we now know that obstruction plays a major role in this disease. The 
presence of obstruction portends a poorer prognosis as compared with non-
obstructive hypertrophic cardiomyopathy.
8 Evaluation of symptomatic patients 
who have mild or no resting gradients (<50 mm Hg) should always include 
provocative maneuvers to determine whether a severe obstruction can be 
provoked. The findings of obstruction, either at rest or during provocation, can 
then be used to target therapy.  
 
Natural History 
Based on more recent, balanced overviews of patients with HCM, the annual 
mortality for patients with HCM is estimated at 1% per year.
9 
Though the 
prognosis of HCM appears better than previously believed, many patients with 
HCM can suffer from a variety of symptoms. First, a subset of patients 
experiences sudden death in the absence of antecedent symptoms. Second, 20% 
of patients develop atrial fibrillation (AF)2, which exacerbates other 
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accompanying clinical symptoms and carries a risk of embolic stroke. Third, the 
patients can experience anginal chest pain because of microvascular ischemia 
from a (blood) supply and demand (excess myocardium) mismatch or, rarely, 
myocardial bridging.
10 Finally the patients may suffer from progressive heart 
failure. This includes patients with preserved or reduced ejection fraction as well 
as those with or without outflow tract obstruction. Any patient with HCM may 
eventually progress to end-stage heart failure with reduced LV systolic 
function.
11 
The evolution to this dilated hypokinetic phenotype of HCM is 
believed to occur progressively as myocardial fibrosis and other adverse 
remodeling changes accumulate.
12-13 
The evolution of severe heart failure (New 
York Heart Association [NYHA] functional class III or class IV) occurs in 10–20% 
of patients with HCM.14 While these symptoms can occur at any age, they are 
most frequently seen in middle-aged adults. The risk of heart failure is 
augmented by the presence and degree of outflow tract obstruction.
15 
Heart 
failure can occur in one-third of patients who have HCM without outflow 
obstruction, though it is less common.16 Further risk factors of heart failure 
include the presence of AF
17 and diastolic dysfunction. Notably, LV wall thickness 
is not predictive of progressive symptoms of heart failure.
18 
 
 
Sudden cardiac death 
Most contemporary series of adult patients with HCM report an annual incidence 
for cardiovascular death of 1–2%, with SCD, heart failure and thromboembolism 
being the main causes of death.19 The most commonly recorded fatal arrhythmic 
event is spontaneous ventricular fibrillation (VF), but asystole, AV block and 
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pulseless electrical activity are described.20 Estimation of SCD risk is an integral 
part of clinical management. A large body of evidence suggests that, in 
adolescents and adults, the risk assessment should comprise of clinical and 
family history, 48-hour ambulatory ECG, TTE (or CMR in the case of poor echo 
windows) and a symptom-limited exercise test. Clinical features that are 
associated with an increased SCD risk shown: age, non-sustained ventricular 
tachycardia, maximum left ventricle wall thickness, family history of sudden 
cardiac death at young age, syncope, left atrial diameter, LVOT obstruction.2 
 
Echocardiography 
Echocardiography is central to the diagnosis and monitoring of HCM. In most 
patients the distribution of left ventricular hypertrophy is characteristically 
asymmetric and particularly heterogeneous, encompassing most possible 
patterns of wall thickening, from extensive and diffuse to mild and segmental, 
and with no single morphologic expression considered typical or classic.21 As 
increased ventricular wall thickness can be found at any location (including the 
right ventricle), the presence, distribution and severity of hypertrophy should be 
documented using a standardized protocol for cross-sectional imaging from 
several projections. 
Assessment of left ventricle wall thickness: 
In patients with known or suspected HCM it is essential that all LV segments 
from base to apex be examined, ensuring that the wall thickness is recorded at 
mitral, mid-LV and apical levels.2 Classical LV hypertrophy cut-off suggestive of 
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HCM in the general adult population is 15 mm. Usually the pattern of LV 
hypertrophy is asymmetrical, with the anterior septum involved in the majority 
of cases being also the site of the maximal LV hypertrophy in most patients. 
Accurate assessment of LV wall thickness can be challenging when hypertrophy 
is confined to one or two segments, particularly in the anterolateral wall or the 
LV apex.  
 
Assessment of LVOTO and SAM: 
Systolic anterior motion of the mitral valve nearly always results in   failure of 
normal leaflet coaptation and mitral regurgitation, which is   typically mid-to-
late systolic and infero-laterally oriented; measurement of the velocity and 
timing of the mitral regurgitation jet helps to differentiate   it from LV outflow 
tract turbulence. SAM-related mitral regurgitation is inherently dynamic in 
nature and its severity varies with the degree of LVOTO. The presence of a 
central or anteriorly directed jet of mitral regurgitation should raise suspicion of 
an intrinsic mitral valve abnormality and prompt further assessment with TOE if 
necessary. By convention, LVOTO is defined as an instantaneous peak Doppler 
LV outflow tract pressure gradient ≥30 mmHg at rest or during physiological 
provocation such as Valsalva manoeuvre, standing and exercise. A gradient of 
≥50 mm Hg is usually considered to be the threshold at which LVOTO becomes 
haemodynamically important.  
Assessment of latent obstruction: 
It is well recognized that some patients without outflow obstruction at rest have 
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gradients that can be provoked by physiological and pharmacological 
interventions that diminish left ventricular end-diastolic volume or augment left 
ventricular contractility. Over 60% of symptomatic patients with apparently 
non-obstructive hypertrophic cardiomyopathy have obstruction during 
exercise.24 Left ventricular outflow tract obstruction in HCM is characteristically 
labile, its magnitude varying spontaneously or following heavy meals and 
ingestion of alcohol. In some cases, obstruction only appears during a 
haemodynamic challenge such as inhalation of amyl nitrite, Valsalva manoeuvre 
and infusion of positive inotropes.
22 
2D and Doppler echocardiography during a   
Valsalva manoeuvre in the sitting and semi-supine position, and   then on 
standing if no gradient is provoked, is recommended in all  patients. Exercise 
stress echocardiography is recommended in symptomatic patients if bedside 
manoeuvres fail to induce LVOTO ≥50 mmHg.  Pharmacological provocation with 
dobutamine is not recommended, as it is not physiological and can be poorly 
tolerated. Similarly, nitrates do not reproduce exercise-induced gradients and 
should be reserved for patients who cannot perform physiologically stressful 
procedures. 23-24
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Figure 2. Protocol for the assessment and treatment of left ventricular outflow tract obstruction.  
 
Assessment of left atrial dimension: 
The left atrium is often enlarged and its size provides important prognostic 
information. The cause of LA enlargement is multifactorial, but the most 
common mechanisms are SAM-related mitral regurgitation and elevated LV 
filling pressures. Although most published studies use antero-posterior LA 
diameter, comparable findings using LA volume indexed to body surface area are 
reported. Given that LA diameter and volume are consistently shown to be 
independently associated with AF, patients with atrial enlargement should be 
monitored on a regular basis.25 
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Assessment of systolic function 
Radial contractile function (EF or fractional shortening) is typically normal or 
increased in patients with HCM. However, EF is a poor measure of LV systolic 
performance when hypertrophy is present.26 Myocardial longitudinal velocities 
and deformation parameters (strain and strain rate), derived from Doppler 
myocardial imaging or speckle tracking techniques, are often reduced despite a 
normal EF and may be abnormal before the development of increased wall 
thickness in genetically affected relatives.27  
 
Assessment of diastolic function 
Patients with HCM often have diastolic dysfunction and the assessment of LV 
filling pressures is helpful in the evaluation of symptoms and disease staging. 
Doppler echocardiographic parameters are sensitive measures of diastolic 
function, but are influenced by loading conditions, heart rate and age, and there 
is no single echocardiographic parameter that can be used as a diagnostic 
hallmark of LV diastolic dysfunction. Therefore, a comprehensive evaluation of 
diastolic function—including Doppler myocardial imaging, pulmonary vein flow 
velocities, pulmonary artery systolic pressure and LA size—is recommended as 
part of the routine assessment of HCM.28 Patients with a restrictive LV filling 
pattern may be at higher risk for adverse outcome, even with a preserved 
ejection fraction.29-30 
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Assessment of symptoms 
Most people with HCM are asymptomatic and have a normal lifespan but some 
develop symptoms, often many years after the appearance of ECG or 
echocardiographic evidence of LVH. It is well know the association of symptoms 
with exertion, post-prandial period and alcohol assumption.31 
- Heart failure: HCM is an important cause of heart failure-related disability over 
a wide range of ages. In some patients heart failure is associated with diastolic 
dysfunction with preserved EF and small LV size; in others, symptoms are 
caused by systolic left ventricular dysfunction or LVOTO (with or without mitral 
insufficiency). Atrial fibrillation can complicate any of these scenarios and 
exacerbate symptoms.
32
 
- Chest pain: Many patients complain of chest pain at rest or on exertion.  The 
causes of chest pain include myocardial ischaemia due to microvascular 
dysfunction, increased LV wall stress and LVOTO. Atherosclerotic coronary 
artery disease may also be responsible.33 
- Syncope: Causes of syncope in HCM include hypovolaemia, complete heart 
block, sinus node dysfunction, sustained ventricular tachycardia, LVOTO, and 
abnormal vascular reflexes.34 Occasionally atrial arrhythmias with fast 
ventricular response can precipitate syncope, particularly in individuals with 
preserved atrial function and high filling pressures.
35 Syncope after prolonged 
standing in a hot environment, or during the postprandial absorptive state, is 
suggestive of neurally mediated syncope, particularly when it is associated with 
nausea and vomiting. Syncope during exertion, or immediately following 
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palpitation or chest pain, suggests a cardiac mechanism.
36 
Provocable 
obstruction should be excluded when patients experience recurrent effort 
syncope in similar circumstances, for example when hurrying upstairs or 
straining.  
- Palpitations: Many patients complain of palpitations, caused by symptomatic 
cardiac contractions and ventricular ectopy. A sustained episode of palpitation 
lasting for more than a few minutes is often caused by supraventricular 
arrhythmia.  
  
Atrial tachyarrhythmia 
Atrial fibrillation is the most common arrhythmia in patients with HCM. 
Predisposing factors include increased left atrial pressure and size, caused by 
diastolic dysfunction, LVOTO and mitral regurgitation. In a recent systematic 
review, the prevalence and annual incidence of AF were 22.5% and 3.1%, 
respectively. Clinical features most closely associated with paroxysmal or 
permanent AF include age and left atrial enlargement. Other possible predictors 
include LVOTO, P-wave duration > 140 ms on signal-averaged ECG, paroxysmal 
SVT, ST-T changes on baseline electrocardiography, premature ventricular 
contractions, late Gadolinium enhancement on CMR, and abnormal coronary 
flow reserve.25 
 
Acute treatment 
New-onset AF is frequently associated with heart failure symptoms and so 
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should be treated promptly. Immediate direct current (DC) cardioversion is 
recommended in haemodynamically unstable patients. If patients have severe 
symptoms of angina or heart failure, intravenous b-blockers or amiodarone are 
recommended.  In haemodynamically stable patients, oral ß-blockers or non-
dihydropyridine calcium channel antagonists are recommended to slow the 
ventricular response to AF. If pre-excitation is present, non-dihydropyridine 
calcium channel antagonists and adenosine are contraindicated. Digoxin should 
be avoided in patients with LVOTO and normal EF. Similarly, Class IC 
antiarrhythmics, such as flecainide and propafenone, should be avoided as they 
may prolong QRS duration and the QT interval, and increase the ventricular rate 
due to conversion to atrial flutter and 1:1 ventricular conduction. When rate 
control is achieved, elective DC cardioversion should be considered after a 
minimum of 3 weeks effective anticoagulation with a vitamin K antagonist 
(VKA). If earlier DC cardioversion is contemplated, a TOE-based strategy should 
be followed.37-38 
 
Thromboembolism prophylaxis 
As patients with HCM tend to be younger than other high-risk groups and have 
not been included in clinical trials of thrombo-prophylaxis, use of the CHA2DS2-
VASc score to calculate stroke risk is not recommended. Given the high incidence 
of stroke in patients with HCM and paroxysmal, persistent or permanent AF, it is 
recommended that all patients with AF should receive treatment with VKA.37-38 
In general, lifelong therapy with oral anticoagulants is recommended, even when 
sinus rhythm is restored. There are no data on the use of new oral anticoagulants 
(NOAC) in patients with HCM, but they are recommended when adjusted-dose 
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VKA (INR 2.0–3.0) cannot be used due to a failure to maintain therapeutic 
anticoagulation or when patients experience side-effects of VKAs or are unable 
to attend- or undertake INR monitoring.39 
 
Ventricular rate control 
Ventricular rate control using b-blockers and non-dihydropyridine calcium 
channel antagonists, alone or in combination, is recommended in patients with 
paroxysmal, persistent or permanent AF.  When adequate rate control cannot be 
achieved, AV node ablation and permanent pacing may be considered. In the 
absence of significant LVOTO, digoxin, alone or in combination with ß-blockers, 
may be used to control heart rate response in patients with AF and an EF < 50%, 
although data on its efficacy in this context are lacking.37-38 
 
Rhythm control 
There are no randomized, controlled trials examining the effect of anti-
arrhythmic drugs or radiofrequency ablation on long-term prevention of AF in 
patients with HCM. Disopyramide is used to treat LVOTO, but its effect on AF 
suppression in HCM is unknown.36 There are few data on catheter ablation for AF 
in patients with HCM but the technique should be considered in patients without 
severe left atrial enlargement, who have drug refractory symptoms or who are 
unable to take anti-arrhythmic drugs.40 
 
Management of symptoms in patients with LVOTO 
General measures 
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All patients with LVOTO should avoid dehydration and excess alcohol 
consumption; weight loss should be encouraged. Arterial and venous dilators, 
including nitrates and phosphodiesterase type 5 inhibitors, can exacerbate 
LVOTO and should be avoided if possible. Digoxin should be avoided in patients 
with LVOTO because of its positive inotropic effects.
2
 
 
Drug therapy 
By consensus, patients with symptomatic LVOTO are treated initially with non-
vasodilating ß-blockers titrated to maximum tolerated dose.41 If ß-blockers 
alone are ineffective, disopyramide, titrated up to a maximum tolerated dose 
(usually 400 – 600 mg/day), may be added. This Class IA anti-arrhythmic drug 
can abolish basal LV outflow pressure gradients and improve exercise tolerance 
and functional capacity without pro-arrhythmic effects or an increased risk of 
sudden cardiac death.42 Verapamil (starting dose 40 mg three times daily to 
maximum 480 mg daily) can be used when ß-blockers are contraindicated or 
ineffective, but close monitoring is required in patients with severe obstruction 
(≥100 mm Hg) or elevated pulmonary artery systolic pressures, as it can 
provoke pulmonary oedema. Short-term oral administration may increase 
exercise capacity, improve symptoms and normalize or improve LV diastolic 
filling without altering systolic function.43 Low-dose loop or thiazide diuretics 
may be used cautiously to improve dyspnea associated with LVOTO, but it is 
important to avoid hypovolaemia. 
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Invasive treatment of LVOTO 
Indication for surgery 
Exertional dyspnea, chest pain, pre-syncope, syncope, fatigue, occasionally 
orthopnea and paroxysmal nocturnal dyspnea can be associated to LVOTO. 
Initially, such symptoms should be treated with medications including high-dose 
β-blockers, verapamil, disopyramide, 44-46 and low-dose diuretics in the presence 
of congestive heart failure. Despite appropriate medication adjustment, however, 
symptom relief can be incomplete, transient and accompanied by intolerable 
drug-related adverse effects. In such patients, providing they have resting or 
provocable gradients of 50 mmHg or more, septal myectomy is the preferred 
treatment. 44  
A long-standing problem facing clinicians caring for patients with HCM is the 
scarcity of robust clinical evidence on which to base therapeutic decisions. For 
most interventions, there are no randomized controlled trial data. Rather, much 
of the literature consists of retrospective observational studies with historical 
controls. Against this background of uncertainty, one area in which there have 
been clear data and a firm consensus is that patients with obstructive HCM who 
have persistent symptoms, or exercise limitation, despite maximum medical 
therapy benefit symptomatically from procedures to reduce the outflow 
gradient. 44 
In approximately 25% of patients with HCM, there is a dynamic obstruction of 
the left ventricular outflow tract caused by septal hypertrophy and systolic 
anterior motion of the mitral valve. Surgical septal myectomy effectively 
abolishes systolic anterior motion of the mitral valve and the concomitant mitral 
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regurgitation, improving left ventricular hemodynamics. Long-term experience 
from a number of centers convincingly shows that this approach is a proven one 
that provides lasting amelioration of symptoms. 47 Moreover, surgical mortality 
in specialist centers is now < 1% to 2%. Despite this, the uptake of surgical 
myectomy is relatively low, with < 5% of patients with HCM being treated in this 
way in most case series. In contrast, there has been a marked proliferation of 
percutaneous, catheter-based, alcohol septal ablation, which achieves 
remodeling in the left ventricular outflow tract by causing a localized myocardial 
infarction in the proximal septum. 48-50 
Although significant controversy exists typically because individual centers 
strongly favor one or other technique and few offer significant experience of 
both, the general consensus is that operative risks, hemodynamic benefits, and 
initial symptomatic benefits are broadly comparable (in centers with 
appropriate expertise) with either technique. A critical difference is that long-
term follow-up data are not yet available for alcohol septal ablation, and there 
are concerns that the intra-myocardial scar may provide a long-term 
arrhythmogenic substrate and that the extent of myocardial damage may exceed 
the target area and lead to further, undesirable, remodeling. Although this 
procedure is associated with an overall success rate of about 80%, there is a high 
incidence of heart block necessitating pacemaker implantation, and the overall 
procedural complication rates could exceed those observed with myectomy. 
Although ablation represents an important therapeutic tool, its role is still to 
define and the consensus panel of physicians experienced in the management of 
HCM has stated that surgical myectomy should be considered as the first option 
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and ablation as an alternative, particularly in those with serious comorbidity or 
advanced age. 44 
Of note, there are alternatives to septal myectomy for HCM patients with drug-
refractory symptoms. Dual-chamber pacemakers were the subject of intense 
scrutiny a decade ago. Although initial case reports and small series showed 
promise, the results of rigorous clinical trials and long-term follow-up suggested 
that these devices provided limited benefit. 51,52 Currently, pacing is considered 
for symptomatic patients with concomitant advanced conduction system disease 
or excessive comorbidities that increase the risk of myectomy unacceptably. 
Ommen et al. 53 report an observational study of 1,337 consecutive patients with 
HCM drawn from four U.S. and European specialist centers between 1983 and 
2001 (Figure 3). These patients were retrospectively grouped into three 
categories: patients with surgically treated outflow tract obstruction, patients 
with medically treated outflow tract obstruction, and patients without 
obstruction. Survival after myectomy was not different from survival in the non-
obstructive group but was better than survival in the non-operated obstructive 
group (for all-cause mortality, HCM-related mortality, and sudden cardiac 
death). The authors concluded that surgical myectomy appears to improve 
survival in patients with highly symptomatic obstructive HCM. 
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Figure 3: Survival in three subgroups of patients with hypertrophic cardiomyopathy: obstructive with surgical myectomy 
(n = 289), obstructive without surgical myectomy (n = 228), and nonobstructive (n = 820). Overall log-rank P <0.001; 
myectomy versus nonoperated obstructive hypertrophic cardiomyopathy P = 0.001; myectomy versus nonobstructive 
hypertrophic cardiomyopathy P = 0.8. © Ommen SR et al. (2005) J Am Coll Cardiol 46: 470–476. 
 
Septal myectomy 
The most commonly performed surgical procedure used to treat LVOTO is 
ventricular septal myectomy (Morrow procedure54), in which a rectangular 
trough that extends distally to beyond the point of the mitral leaflet–septal 
contact is created in the basal septum below the aortic valve. This abolishes or 
reduces LV outflow tract gradients in over 90% of cases, reduces SAM-related 
mitral regurgitation, and improves exercise capacity and symptoms. Long-term 
symptomatic benefit is achieved in 70–80% of patients with a long-term survival 
comparable to that of the general population. The main surgical complications 
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are AV nodal block, ventricular septal defect and aortic regurgitation (AR), but 
these are uncommon in experienced centers using intraoperative TOE guidance. 
When there is co-existing mid-cavity obstruction, the standard myectomy can be 
extended distally into the mid-ventricle around the base of the papillary muscles, 
but data on the efficacy and long-term outcomes of this approach are limited. 
Concomitant mitral valve surgery is required in 11–20% of patients undergoing 
myectomy. In patients with marked mitral leaflet elongation and/or moderate-
to-severe mitral regurgitation, septal myectomy can be combined with one of 
several adjunctive procedures, including mitral valve replacement, posterior-
superior realignment of the papillary muscles, partial excision and mobilization 
of papillary muscles, anterior mitral leaflet plication, and anterior leaflet 
extension using a glutaraldehyde-treated pericardial patch that stiffens the mid-
portion of the leaflet. An elongated anterior mitral leaflet favours mitral valve 
repair instead of replacement. Surgical mortality for myectomy with mitral 
intervention is around 3–4%. 
The learning curve for performing this procedure is considerable, however, and 
early surgical experience was associated with complications of complete heart 
block, ventricular septal defect, injury to the aortic or mitral valves, and 
incomplete relief of obstruction.  
 
- History of surgical treatment 
Surgical treatment of obstructive HCM began in the late 1950s. The first surgical 
procedures proposed for relief of left ventricular outflow tract obstruction 
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(LVOTO) involved a simple incision in the basal septal bulge, sometimes 
deepened with the surgeon’s finger (myotomy), or excision of muscle 
(myectomy).53-59 
Cleland described the first procedure for surgical treatment of LVOTO in 1960, 
which comprised a limited transaortic septal myectomy.55 Since then, many 
different surgical procedures have been described. Historically, access to the 
septum has been obtained through the aorta, left ventricle, right ventricle or left 
atrium; however, the transaortic approach remains the primary method used. A 
decrease in left ventricular outflow gradient is accomplished by enlargement of 
the outflow tract and interruption of the pathophysiological sequence of events 
that are responsible for the outflow gradient (primarily systolic anterior motion 
[SAM] of the anterior mitral leaflet). Complete relief of LVOTO by septal 
myectomy also eliminates mitral value regurgitation caused by SAM. Any 
residual mitral valve regurgitation after adequate septal myectomy is almost 
always caused by intrinsic mitral valve abnormalities such as ruptured chordae, 
leaflet prolapse or annular dilatation, and can be corrected by direct valve repair. 
Replacement of the mitral valve, once proposed as an alternative to septal 
myectomy, can eliminate the left ventricular outflow gradient and improve 
symptoms. The chief disadvantage of this procedure is that outflow obstruction 
is merely replaced with the risks of durability, infection, thromboembolism and 
anticoagulation that are associated with prosthetic valves. Mitral valve 
replacement is now reserved for patients with primary mitral valve pathology 
(e.g. rheumatic valve disease) not amenable to repair. 
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- Surgical technique 
Operations are guided by intraoperative transesophageal echocardiography 
(TOE) with particular attention paid to the septal anatomy and thickness, and 
mitral valve function. Access is gained through a median sternotomy and direct 
intracardiac pressures are measured simultaneously in the left ventricle and 
aorta. If the left ventricular outflow tract (LVOT) gradient is low (<30 mmHg) 
because of anesthesia, isoproterenol is administered or premature ventricular 
contractions are induced to determine the maximal gradient. Standard 
cardiopulmonary bypass with normothermia or mild hypothermia (32–34 °C) is 
used, and during aortic occlusion, the heart is protected by infusion 
(approximately 1,000 ml) of antegrade cold blood cardioplegia into the aortic 
root, followed by additional doses administered selectively into the left and right 
coronary ostia every 10–20 min. A transverse aortotomy is made, carried 
rightward toward the noncoronary sinus and down to the aortic annulus, and 
retracted with pledgeted sutures. Optimum visualization of the ventricular 
septum is facilitated by posterior displacement of the left ventricle with sponge 
forceps. In addition, a small rake retractor can be used to engage the distal 
septum so that it can be pulled cephalad toward the aortic annulus. The incision 
begins in the septum at the nadir of the right aortic sinus and continue leftward 
toward the mitral valve. Importantly, the incision should be continued apically 
beyond the point of mitral–septal contact (usually marked by a fibrous friction 
lesion). The resection is then extended in several ways, beginning with continued 
resection leftward toward the mitral valve annulus and apically to the bases of 
the papillary muscles. This wide incision beneath the valve improves exposure of 
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the important area toward the apex. Resection from the apical third of the 
septum to the right of the coronary cusp incision is then performed, effectively 
making a much wider trough at the apex than the base. All areas of papillary 
muscle fusion to the septum or ventricular free wall are divided, and anomalous 
chordal structures and fibrous attachments of the mitral leaflets to the 
ventricular septum are divided or excised. If desired, the resected area can be 
deepened with a rongeur. The adequacy and distal extent of resection are 
evaluated by direct inspection and digital palpitation. The most common reason 
for residual gradients is incomplete extension of the septectomy toward the apex 
of the heart. In general, the bases of the papillary muscles can be visualized while 
looking through the aortic root after the myectomy has been completed. The 
aortic and mitral valves are inspected to insure they have not been injured. After 
the patient is weaned from cardiopulmonary bypass, pressures are remeasured 
in the left ventricle and aorta and TOE evaluation is repeated. If myectomy has 
been successful, there will be little or no residual gradient, and little or no SAM of 
the mitral valve. In general, if the gradient were greater than 15–20 mmHg, a 
cardiopulmonary bypass would be resumed for re-resection. Transthoracic 
echocardiographic evaluation is routinely performed before hospital discharge. 
- Abnormal mitral apparatus 
Some symptomatic patients with obstructive HCM have associated anomalies of 
the mitral sub-valvular apparatus, which, if unrecognized and untreated, can lead 
to incomplete or temporary relief of obstruction only.60 These anomalies include 
direct papillary muscle insertion into the anterior mitral leaflet, extensive fusion 
of papillary muscle(s) to the ventricular septum or left ventricular free wall, 
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abnormal chordae tendineae that attach to the ventricular septum or free wall 
(‘false cords’), and accessory papillary muscles, all of which can tether the mitral 
leaflets towards the septum and contribute to LVOTO. Obstructive HCM 
associated with anomalous papillary muscles or chordae could be treated 
successufully without mitral valve replacement by surgical relief of the 
anomalies and an extended septal myectomy. 
In selected patients with obstructive HCM and severe mitral regurgitation caused 
by primary valvular disease (e.g. prolapse or myxoma, or ruptured chordae), 
mitral valve repair, in addition to myectomy, is the most appropriate treatment.  
Occasionally, intrinsic mitral valve disease is severe enough to preclude repair 
(e.g. rheumatic mitral stenosis and regurgitation) and mitral valve replacement 
is, therefore, prudent.  
 
- Long term results 
Septal myectomy has been established as a proven approach for reversing the 
consequences of heart failure. This technique provides permanent amelioration 
of obstruction (and relief of mitral regurgitation) at rest, and restores functional 
capacity and an acceptable quality of life at any age, exceeding that achievable 
with chronic administration of cardioactive drugs.44 These benefits can be 
demonstrated both subjectively by patient history, and objectively by increased 
treadmill time, maximum workload, peak oxygen consumption, and improved 
myocardial oxygen demand, metabolism and coronary flow. 44 
Gradient reduction results from basal septal thinning with resultant enlargement 
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of the LVOT area (and redirection of forward flow with loss of the drag and 
Venturi effects on the mitral valve).61-63 As a consequence, SAM of the mitral 
valve and mitral–septal contact are abolished. 62 Mitral regurgitation is usually 
eliminated without the need for additional mitral valve surgery, left ventricular 
systolic wall stress and left ventricular end-diastolic pressures are 
normalized.44,61 Heart failure resulting from obstructive HCM can, therefore, be 
regarded as surgically correctable. 
When considering HCM-related mortality after septal myectomy, long-term 
survival was 99%, 98% and 95%, at 1, 5 and 10 years, respectively. 53 
Myectomy was also associated with reduced long-term risk for sudden cardiac 
death. Nonetheless, surgical myectomy does not eliminate the need to assess 
each patient’s risk for sudden cardiac death and to consider implantable 
cardioverter-defibrillator (ICD) placement in those with a clinically significant 
risk burden (i.e. positive family history of sudden cardiac death, ‘massive’ left 
ventricular hypertrophy, non-sustained ventricular tachycardia etc.). 
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PURPOSE OF THE STUDY 
To measure the long term effects of a successful left ventricular septal myectomy 
on LA remodeling in patients with obstructive HCM. 
To describe the possible influence of the septal myectomy on the prevalence of 
atrial arrhythmias in this group of patients.  
 
 
METHODS 
Population 
The study population consists of 133 consecutive patients with obstructive HCM 
evaluated at The Heart Hospital (University College London Hospital) who 
underwent a successful septal myectomy were included in this retrospective 
study.  
 
Preoperative, operative, and postoperative data were obtained from the Heart 
Hospital HCM database and from medical record review; data were de-identified 
before analysis. 
 
 
Criteria of inclusion 
Patients aged >18 years who underwent septal myectomy for refractory 
symptoms (NYHA functional class IIb-IV) despite optimal medical therapy at our 
institution from October 2003 to August 2013, were eligible for inclusion in the 
study.  According to 2014 ESC Guidelines, the diagnosis of HCM was based on the 
presence of a wall thickness ≥15 mm in one or more LV myocardial segments as 
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measured by any imaging technique (echocardiography, cardiac magnetic 
resonance imaging (CMR) or computed tomography (CT)) that is not explained 
solely by loading conditions. The clinical diagnosis of HCM in first-degree 
relatives of patients with unequivocal disease is based on the presence of 
otherwise unexplained increased LV wall thickness ≥13 mm in one or more LV 
myocardial segments, as measured using any cardiac imaging technique 
(echocardiography, CMR or CT).3 By convention we defined HCM as significantly 
obstructive in patients who satisfied one of the following criteria based on 
echocardiography: (1) rest LVOT peak gradient > 30 mmHg or (2) provoked 
(Valsalva maneuver or exercise) LVOT peak gradient > 50 mmHg. Labile LVOT 
obstruction was defined as the presence of provoked LVOT obstruction (peak 
gradient > 50 mmHg) in the absence of rest LVOT obstruction (peak gradient ≤ 
30 mm Hg).  The diagnosis of AF was based on electrocardiogram (ECG) or 
Holter monitoring at the visit, or by a documented history of AF. 
 
Surgery  
The decision to perform surgery was made after consensus of a heart team 
consisting of a cardiothoracic surgeon, an interventional cardiologist, and a 
cardiologist specialized in HCM care. The surgical technique has been described 
previously. In brief, after induction of the anesthesia the surgeon opens the 
ascending aorta by an oblique incision, myectomy is performed to the left of an 
imaginary line through the nadir of the right coronary cusp in the beginning with 
a locally designed electrocautery device, later by excision with scissors and a 
rongeur or surgical knife. The surgical results are assessed with transesophageal 
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echocardiography immediately after weaning from cardiopulmonary bypass and 
at a systolic blood pressure of > 100 mm Hg. 
Patients who underwent surgical myectomy in association with other 
procedures (i.e. mitral valve surgery) were excluded from the analysis.  
 
Echocardiography assessment 
Using the recommendations from the European Society of Echocardiography, 2D 
and Doppler echocardiographic measurements were performed. Every patient 
underwent a complete echo study performed by Cardiac Physiologist of the 
Diagnostic Testing Unit (DTU). 
Left atrial antero-posterior diameter was measured in parasternal long axis, 
perpendicularly to the LA walls. The measurement of the LA diameter was in 
end-systole, from leading edge of the posterior aortic wall to the leading edge of 
the posterior LA wall. It could be measured in 2D, or in M-mode if the ultrasound 
beam was perpendicular to the LA walls. 
LVOT gradient was measured using continuous wave Doppler in either the apical 
4-chamber or apical 3-chamber view to determine the peak gradient at rest or 
under provocation.  
Assessment of Systolic anterior motion and mitral valve regurgitation was 
performed using 2D, color and Doppler in both the parasternal long axis view 
and apical 4- 5- and 3-chamber. 
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Follow up 
Baseline measurement were obtained pre surgery (T0), first follow up post 
procedure (T1) and at last follow up (T2).  
LA dimensions, the presence of SAM and MR were obtained by transthoracic 
echocardiogram at each time interval.  
Patients were excluded if preoperative and postoperative echocardiograms were 
not available for review. Survival status was determined by review of electronic 
medical records, patient correspondence, and cause of death were adjudicated 
by review of medical examiner record when possible. 
 
Statistic methods 
Statistical analysis was performed using the SPSS software. Continuous variables 
were expressed as mean±SD, and categorical variables as percentages. 
Numerical values were compared using the Mann-Whitney U test or student’s t 
test, and categorical values using the χ2 test. 
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RESULTS 
Table 1 shows the baseline characteristics of the 133 patients affected by 
obstructive hypertrophic cardiomyopathy who underwent surgical septal 
myectomy. Patients who had a mitral valve surgery were excluded. 
Number of patients  133 
Male  69% 
Age at myectomy 47 ±13 years  
NYHA Functional Class IIb-IV 
LA diameter   47±7 mm 
Complete SAM  74% 
Moderate or severe MR  37% 
Mean LVOT gradient 97±33 mmHg  
Paroxysmal atrial fibrillation 14 (10.5%) 
Persistent/permanent atrial fibrillation 2 (1.5%) 
Beta-blocker/calcium-channel antagonists 92% 
Disopyramide  52% 
Amiodarone 12% 
 
Table 1: Clinical and echocardiographic characteristics at baseline of the study population  
 
The mean age of the population at myectomy was 47 ±13 years (85 males, 69%).  
All patients were severely symptomatic (NYHA functional class IIb-IV) despite 
optimal medical treatment. At baseline, LA diameter was 47±7 mm; complete 
SAM was detected in 74% while moderate or severe MR was detected in 37% of 
patients. Mean LVOT gradient at baseline was 97±33 mmHg. 
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Before surgery, 117 (10.5%) patients were in sinus rhythm and their mean age 
at myectomy was 46±14 years (minimum 18, maximum 76); 14 (1.5%) patients 
had a history of paroxysmal atrial fibrillation (mean age at myectomy 53±8 
years, minimum 41, maximum 68); 2 patients had persistent/permanent atrial 
fibrillation (mean age at myectomy 63 years, minimum 62, maximum 65).  The 
difference of age at myectomy between the three groups was statistically 
significant (p=0.034), being the patients in AF significantly older than those in 
SR. Figure 1 
 
Figure 1: at the base-line (AF pre) 
1. Patients in sinus Rhythm 
2. Patients with paroxysmal atrial fibrillation 
3. Patients with persistent/Permanent atrial fibrillation 
 
Regarding the medical therapy at baseline: 92% of patients were on beta-
blocker/calcium-channel antagonists, 52% on disopyramide and 12% on 
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amiodarone. 
After myectomy  
First follow up post procedure (T1) was at a mean time of 1.7± 1.6 months and 
last follow up (T2) after surgery was at a mean time of 5.1±2.8 years (T2).  
As expected, septal myectomy resulted in a significant and persistent reduction 
of LVOT gradient (14±17 mmHg at T2, p<0.001), reduction of complete SAM 
(2%, p<0.001 at T2) and reduction of severity of MR (1%, p<0.001), with an 
important clinical improvement in all patients (NYHA Class I-II). Regarding the 
medical therapy at the last follow up, 84% of patients were on beta-blocker or 
calcium-channel antagonists (p=0.04), 1% on disopyramide (p<0.001) and 10% 
on amiodarone (p=NS). 
After surgery, at post operative follow up (T1) there was a significant decrease of 
LA diameter (45.2±7 mm, p=0.001). At T2 the LA diameter was 45.3±6 mm. Pair 
sample analysis of the difference of the LA size T0-T1 and T0-T2 showed long-
term reduction (-1.8 mm, p=0.001, -1.72 mm, p=0.001) with no significant 
difference between early and long-term effects (T1-T2 -0.12, p =0.07). Figure 2 
.  
 
 
Figure 2 Mean left atrial diameter at baseline and during first (LA post, T1) and last follow-up (LA 
last, T2) 
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In the post-operative period (T1), 86 patients were in sinus rhythm and their 
mean age at myectomy was of 43±13 years (minimum 18, maximum 73); 45 
patients had paroxysmal atrial fibrillation (mean age at myectomy 55±11 years, 
minimum 25, maximum 76); 2 patients remained in persistent/permanent atrial 
fibrillation (mean age 63, minimum 62, maximum 65).  The difference of age at 
myectomy between the three groups was statistically significant (p=0.001). 
At the last follow up (T2), 91 patients were in sinus rhythm and their mean age 
at myectomy was 45±14 years (minimum 18, maximum 76); 26 patients had 
paroxysmal atrial fibrillation (mean age at myectomy 51±13 years, minimum 18, 
maximum 68); 16 patients were in persistent/permanent atrial fibrillation 
(mean age  53±10 years, minimum 36, maximum 63). The difference of age at 
myectomy between the three groups was statistically significant (p=0.024). 
Figure 3 
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Figure 3: in the last follow-up (AF last) 
1. Sinus Rhythm 
2. Paroxysmal atrial fibrillation 
3. Persistent/Permanent atrial fibrillation 
 
Age at myectomy and atrial fibrillation burden at last follow up  
At the last follow up (T2, 5.1± 2.8 years), 91 (68%) patients were in sinus rhythm, 
26 (20%) patients had paroxysmal atrial fibrillation, 16 (12%) patients had 
persistent/permanent atrial fibrillation.  
Among the 60 patients who were under 45 years at myectomy, 48 (80%) were in 
sinus rhythm at the last follow up, 8 (13.3%) had paroxysmal atrial fibrillation 
and  4 (6.7%) had persistent/permanent atrial fibrillation.  
Among the 73 patients who were older than 45 years at the time of myectomy, 
43 (58.9%) was in sinus rhythm at last follow-up; 18 (24.7%) had paroxysmal 
atrial fibrillation and 12 (16.4%) had persistent/permanent AF at the last follow-
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up. The burden of AF accordingly to age at myectomy (older or younger than 45) 
was significantly different (p 0.05). 
Before the myectomy, there was no significant difference in terms of LA diameter 
between patients <45 years (mean LA diameter 46.9 mm) and >45 years (mean 
LA diameter 47.21 mm,  p=0.8), yet, in the last follow-up after surgical myectomy 
(T2), those >45 years had bigger LA diameters (mean LA diameter 46.75 mm) 
than those younger (mean LA diameter 43.62 mm, p<0.05). 
 
 
DISCUSSION  
The LVOT obstruction in patients affected by hypertrophic cardiomyopathy has 
been considered for a long time only a determinant of symptoms, such as 
dyspnea, angina and exertional syncope. More recently, it has been 
demonstrated that resting dynamic obstruction is a powerful predictor of heart 
failure and sudden cardiac death.15 Therefore, correct management of LVOT 
obstruction is essential. Patients with LVOT obstruction who are not treated or 
treated too late tend to develop left atrial dilatation and atrial fibrillation, which 
are adverse prognostic elements in the long-term outcome.64 
Septal myectomy is currently considered the best treatment for severely 
symptomatic patients despite maximal medical treatment. Good long-term 
outcome data support its efficacy and safety. It is well established that septal 
myectomy produces a significant reduction in LVOT gradient with subsequent 
improvement in mitral regurgitation due to SAM and cardiovascular symptoms. 
LVOT obstruction is strongly correlated with worsening LV diastolic function 
and increasing LA size.   
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The fact that, in patients who have undergone a successful surgical myectomy, 
two of the most important factors for prognosis are atrial dilatation and atrial 
fibrillation, suggests that a late surgical timing could be not beneficial. 64  
In our study it has been observed that LA diameter reduction follows after 
successful reduction of LVOT obstruction with surgical myectomy in patients 
with HCM. Reassuringly, this positive atrial remodeling appeared to be sustained 
at long-term follow up in this group of patients.  
We based our conclusion on a conventional and easy to obtain measurement: the 
antero-posterior LA diameter, which is a component of any clinical 
echocardiographic study. As previously demonstrated by Nistri and coll., LA 
diameter is a simple but powerful predictor of long-term disease progression 
and outcome in patients with hypertrophic cardiomyopathy. 65 
The significant reduction of LA antero-posterior diameter observed in our data 
may reflect the interruption of the vicious cycle secondary to the LVOT 
obstruction. 
The information derived by the left atrium are crucial in order to understand the 
clinical phenotype of our patient. A left atrium enlargement is a marker of both 
diastolic dysfunction and mitral regurgitation in patients with HCM and can be 
also one of the determinants of the risk to experience AF, with its complications 
in terms of thromboembolism and heart failure. 
In our data, in accordance with the literature, we observed that the more the 
patients got older, the more they experienced atrial fibrillation. This trend 
appeared not to be influenced by the myectomy. Yet, our data suggested that 
there might be an increased benefit on left atrial reversal remodeling if surgical 
myectomy is performed before the age of 45. In fact, at the base-line, before the 
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surgical procedure, there was no significant difference in terms of LA diameter 
between the group of patients older than 45 years old than those younger. On 
the contrary, after successful myectomy, the mean LA diameter in patients who 
had undergone the procedure earlier the age of 45, had a significant smaller LA 
diameter than those undergoing myectomy later. Furthermore, the burden of AF 
at last follow-up appeared to be critically related to the age at myectomy in our 
population with significantly lower prevalence of AF in patients younger than 45 
at myectomy.  
We have not collected information about presence and extension of fibrosis in 
the left atria. Atrial fibrosis could be related to both the severity of the 
ventricular hypertrophy and the diastolic dysfunction before myectomy but the 
relationship with AF susceptibility still needs to be fully understood. 
 
CONCLUSION 
Patients with hypertrophic obstructive cardiomyopathy who are not treated or 
treated too late tend to develop left atrial dilatation and atrial fibrillation, which 
are adverse prognostic elements in the long-term outcome. The surgical septal 
myectomy significantly reduces the left atrial diameter in the first months after 
surgery and the benefit is maintained during follow-up. Our data suggested that 
there might be an increased benefit on left atrial reversal remodeling if surgical 
myectomy is performed before the age of 45. 
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